Deletions of the 3p arm have been detected in various solid tumors, but no study to date has investigated this deletion in diffuse large B-cell lymphoma (DLBCL). Recently, we demonstrated that 3p14.2 was deleted in approximately 30% of DLBCL cases by use of a genome-wide arraycomparative genomic hybridization (CGH). For a more detailed examination of the genomic losses at 3p14.2, here we made use of contig BAC array for 3p14.2, and found that 12 DLBCL samples displayed losses. All of the deleted regions were located within the fragile histidine triad (FHIT) gene, and the most frequent region of loss was mapped to 0.4 Mbp of the region encompassing the introns 4 and 5 and exon 5 of the FHIT gene. Concomitant analysis of transcripts showed that the FHIT gene was aberrantly transcribed in 31% of the DLBCL samples examined and that the lost exons of the aberrant transcripts were correlated with genomic deletions. These findings indicate that (1) loss of genomic material at 3q14.2 is responsible for exon losses of the FHIT gene, and (2) genomic loss of the FHIT gene is one of the causes of the generation of aberrant transcripts.
Introduction
Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin's lymphoma (NHL), accounting for 30-40% of adult NHL (Harris et al., 1994) . Genomic alterations in DLBCL have been investigated by various methods. Many regions of chromosomal amplifications, losses and translocations such as rearrangements of BCL-6 and BCL-2 (Kramer et al., 1998) were detected by means of comparative genomic hybridization (CGH) (Barth et al., 1998; Berglund et al., 2002; Karnan et al., 2004) , G-banding (Cigudosa et al., 1999) and fluorescence in situ hybridization (FISH) (Dave et al., 2002) . Recently, small genomic amplifications containing oncogenes were detected by array CGH in DLBCL (Wessendorf et al., 2003) . However, genomic deletions of tumor suppressor genes in DLBCL are not yet fully understood.
We recently performed array CGH (Solinas-Toldo et al., 1997; Pinkel et al., 1998) covering the whole genome in DLBCL cases, and detected a genomic deletion at 3p14 in about 30% of patients and cell lines . Genomic deletions of the 3p arm have been reported in many solid tumors and leukemias (Huebner and Croce, 2001 ), but no study published to date has reported genomic deletions of this region in DLBCL.
The fragile histidine triad (FHIT) gene, located at chromosome 3p14.2, is 1.6 Mbp in size and encodes an mRNA of 1.1 kbp Matsuyama et al., 2003) and has the features of a tumor suppressor gene (reviewed in Pekarsky et al., 2002) . Genomic deletions and aberrant transcripts lacking certain exons of the FHIT gene have been observed in most common forms of cancer including breast , lung (Sozzi et al., 1996) and head and neck (Virgilio et al., 1996) cancer and leukemias (Iwai et al., 1998; Albitar et al., 2001) . Cell lines exhibiting genomic deletions of the FHIT gene showed aberrant transcripts and absence or diminution of the Fhit protein (Druck et al., 1997) . It is therefore conceivable that the FHIT gene is the target one of the genomic deletion at 3p in DLBCL.
In the study presented here, to detect the target gene of the deletion at 3p14.2, we examined the genomic structure by means of array CGH of DLBCL using slides spotted with 27 BAC clones. We also examined transcripts of the FHIT gene to investigate the relationship between genomic loss and transcript abnormality.
Results

Construction of array CGH for FHIT gene
Genome-wide array CGH analyses of 66 DLBCL cases showed genomic loss at 3p14, which contains FHIT as the single known gene . For a more detailed examination of the genomic losses, we have constructed a genomic array with BAC clones for 3p14. A total of 27 BAC clones encompassing the FHIT gene (4 Mbp in length, see Figure 1 and Table 1) were selected on the basis of the NCBI Map Viewer Build 34 version (http://www.ncbi.nlm.nih.gov/mapview). For the normalization of data, five BAC clones representing neither amplification nor deletion in any of the 66 DLBCL cases tested (data not shown) were used (Table 1) .
To evaluate the quality of the array slides constructed, we hybridized normal male versus normal male DNAs three times independently. Log2 ratios of each clone were within the range of À0.04 to þ 0.06, À0.02 to þ 0.08 and À0.07 to þ 0.01, respectively (Figure 2) , and the standard deviation (s.d.) of the log2 ratios for each clone fell within the range of 0.01-0.04 (mean 0.028). Since the mean log2 ratios 73 s.d. were within the range of À0.16 to þ 0.16, we defined log2 ratios of À0.2 or below as representing genomic loss.
Genomic loss at the 3p14.2 in DLBCL
The samples subjected to array CGH were selected on the basis of result of reverse transcriptase-polymerase chain reaction (RT-PCR) analysis in 57 DLBCL samples including six cell lines. We analysed 18 samples with aberrant transcripts, one sample without any transcript, and eight samples with only wild-type transcripts for normal control. Contig array CGH for 3p14 revealed that seven cases and five cell lines Table 1 ) Figure 2 Array CGH profiles of three independent hybridizations of normal male versus normal male DNAs. The log2 ratios representing the ratios of tested samples over reference samples after log2 transformation, normalization and averaging of triplicate scores are indicated as black circles in the graph. The number on the X-axis represents one of the BAC clones listed in the Table 1 FHIT is the deleted gene at 3p14.2 in DLBCL Y Kameoka et al displayed genomic loss. Figure 3a shows three representative profiles. The lengths of the regions of loss were various, ranging from 100 kbp (Figure 3a , middle) to 1 Mbp (Figure 3b , case 899-798). All the regions of loss fell within the range of 59.4-61.2 Mbp (1.8 Mbp in span) from the telomere of the 3p (Figure 3b ), and were found to be located precisely within the whole FHIT gene. The most frequent region of loss at 3p14.2, seen in four cases and four cell lines, was within the range of 60.1-60.4 Mbp (BAC number 12, 13 and 14), which included exon 5 and parts of introns 4 and 5 of the FHIT gene ( Figure 3b ). Figure 4a shows the averages of log2 ratios for each BAC clones as calculated for 12 samples showing loss at 3p14.2. The region corresponding to BACs 12, 13 and 14 in the middle of the FHIT gene was found to represent the most prominent region of loss, with three samples (1077-912, OCI-LY3, OCI-LY13.2) showing log2 ratio o-1 (Figure 4b ). BAC clone 14 (RP11-48E21) encoded exon 5 of the FHIT gene, which contains the start codon.
Aberrant transcripts of the FHIT gene in DLBCL
We subjected 57 DLBCL samples to nested reverse transcriptase-polymerase chain reaction (RT-PCR) analysis, 27 samples of which were also examined by means of array CGH. In addition to the wild-type FHIT transcripts, products of various sizes were found amplified in 18 (31%) of the 57 samples ( Figure 5 ). Cell line OCI-LY17 did not show any FHIT transcripts, which is indicative of homozygous deletion. Cell line OCI-LY3 exhibited two aberrant transcripts of different size without expected size of wild-type transcript, while the remaining 17 samples showed one aberrant transcript in addition to a wild-type transcript.
The aberrant RT-PCR products were excised from an agarose gel and directly sequenced. Exon structures of the aberrant transcripts thus found are shown in Figure 6 . Most of the aberrant transcripts were generated as a result of abnormal fusion of either exon 3 (10 cases) or exon 4 (three cases) with one of the downstream exons, with one or more intervening exons FHIT is the deleted gene at 3p14.2 in DLBCL Y Kameoka et al being skipped. The fused downstream exons were various: exon 8 (six samples), exon 7 (one sample) exon 9 (two samples), exon 10 (one sample) and exon 5 (two samples). Unknown sequences were found inserted in the aberrant transcripts of NOL3, OCI-LY1, 810-768, 637-618 and OCI-LY13.2, These inserted sequences were of different sizes, did not contain any repetitive sequences, and showed no significant homology to any known sequences in the GenBank database. Exon 5 containing the start codon of the FHIT gene was lost in the aberrant transcripts in 16 out of 18 samples examined.
Correlation of genomic loss and aberrant transcripts
Results of array CGH and RT-PCR for the FHIT gene are summarized in Table 2 . It was remarkable that 11 out of the 12 samples with the genomic loss exhibited aberrant FHIT transcripts (nos. 1-11), and one sample with the genomic loss exhibited no FHIT transcript (no. 12). Results of samples without detectable genomic loss of the FHIT locus are mixed. Seven samples exhibited aberrant transcripts (nos. 13-19), and eight (nos. 20-27) only normal transcripts. Representative profiles relating genomic loss to aberrant transcripts are presented in Figure 7 . The sample 899-798 with approximately 1 Mbp of genomic deletion expressed the aberrant transcript, which lacked the exactly corresponding exons 4-8 (Figure 7a ). There were some discrepancies between the genomic loss regions and the aberrant transcripts in two cases, where exons 5-7 of the transcripts were deleted while the corresponding genomic regions for exons 6 and 7 were not lost (Figure 7b ). Cell line OCI-LY3 showed two discontinuous genomic deletions at BACs 12-14 and BAC 17 ( Figure 7c ) and was found to have two aberrant transcripts, one without exon 4 and the other without exons 5-7. When the regions of genomic loss and the exons used in the aberrant transcripts were aligned for OCI-LY3, one could speculate that two regions of genomic loss were in different alleles, thus leading to respective two aberrant transcripts.
Discussion
Many efforts have been made to delineate the genomic alterations of DLBCL (Barth et al., 1998; Cigudosa et al., 1999; Berglund et al., 2002; Dave et al., 2002 , but the 3p arm has not been . In the study presented here, we constructed the BAC contig for 4 Mbp at 3p14.2 for array CGH analysis, and found that almost all of the deleted regions at 3p14.2 in DLBCL were located within the FHIT gene. The proposition that FHIT is a tumor suppressor gene involved in solid tumors in various ways (reviewed in Pekarsky et al., 2002) , especially with respect to tumor progression (Fong et al., 2000) , and also as a molecule affecting the clinical outcome of DLBCL cases (Chen et al., 2004) , suggests that genomic deletions of the FHIT gene are involved in the progression of DLBCL. The minimal detectable size of deletions in our study was of the order of 0.1 Mbp, thus allowing for analysis of genomic alterations hitherto unrecognized by conventional CGH methods. With this advantage of high resolution, we were able to identify the most frequent region of loss as a 0.4 Mbp region encompassing introns 4 and 5 and exon 5 of the FHIT gene. The proposed most unstable site was found at BAC 14 (RP11-48E21), which contains exon 5 with the start codon of the FHIT gene , making it temping to speculate that deletions in exon 5 may account for reduced expression of the FHIT proteins seen in DLBCL cases (Chen et al., 2004) . This frequent region of loss also matches a human common fragile site, FRA3B (Smeets et al., 1986) . FRA3B is the most highly fragile site in the human genome, in which unstable sequences with repeats and transposons are included (Huebner and Croce, 2001 ). The unstable sequences of FRA3B may account for frequent genomic deletions of the FHIT gene in DLBCL as it does in other solid tumors.
To the best of our knowledge, few studies have demonstrated a relationship between aberrant transcripts and genomic loss of the FHIT gene. Cell lines with genomic deletions of the FHIT gene showed aberrant transcripts (Druck et al., 1997) . To clarify the relationship between aberrant transcripts and genomic losses, we compared FHIT transcripts with the corresponding genomic losses. Aberrant transcripts or loss of expression was detected in 33% (19 of 57) of the DLBCL samples. This frequency is lower than that found in many other solid tumors. The reported frequency of these findings in lymphoid malignancies varies such as 20-70% in acute lymphoblastic leukemia (Iwai et al., 1998; Hallas et al., 1999; Albitar et al., 2001) and 80% in Burkitt's lymphoma cell lines (Ferrer et al., 1999) . However, the proportion of the altered transcripts may be depending on their histological classification. Sequence analysis of the aberrant transcripts of different sizes identified several types of exon skipping, with aberrant transcripts lacking the exons 5-6 most commonly observed, as they have been in various other tumors (Gemma et al., 1997; Hendricks et al., 1997) . All of the 12 cases with genomic deletion showed aberrant transcripts. The skipped exons in the FHIT transcript were concordant with the regions of genomic loss detected by array CGH. Interestingly, the OCI-LY3 cell line exhibited two discontinuous deletions in the FHIT gene and produced two kinds of aberrant transcripts, raising the possibility that genomic deletions are located in different alleles, thus leading to the corresponding two transcripts. Taken together, these results indicate that genomic deletions, at least in part, account for the generation of aberrant transcripts.
On the other hand, seven cases with apparently normal genomic configurations produced aberrant transcripts. This suggests that some minute genomic alterations, undetectable even with our array CGH, could generate these aberrant transcripts. Alternatively, epigenetic mechanisms may be operating, as suggested by early studies reporting aberrant transcripts in normal hematopoietic cells (Peters et al., 1999) , and cell lines that retain all FHIT exons yet express only aberrant transcripts .
The study by Chen et al. (2004) showed that decreased FHIT protein expression indicated a significantly worse prognosis in DLBCL. However, clinical significance was not observed between cases with or without genomic loss at 3p14.2 in DLBCL . The discrepancy between these studies may be caused by the difference in the evaluation method for FHIT gene, and this may indicate that the cause of the FHIT gene inactivation is not only genomic loss.
In conclusion, a contig array CGH enabled us to identify for the first time the involvement of alterations of the FHIT gene in DLBCL, as well as detect various genomic deletions at 3p14.2 in DLBCL. The most frequent region of genomic deletion was found to be located at exon 5 of the FHIT gene. Two-thirds of the FHIT is the deleted gene at 3p14.2 in DLBCL Y Kameoka et al aberrant FHIT transcripts were found to correlated with the losses of the corresponding genomic regions, indicating that genomic loss is one of the causes of aberrant transcripts.
Materials and methods
Sample tissues and cell lines
In this study, We selected samples with both DNA and RNA available. Surgical resection provided 45 DLBCL tissue specimens from the Aichi Cancer Center and six samples from the Fujita Health University School of Medicine. All cases were classified by using the World Health Organization (WHO) classification (Harris et al., 1999) . The cell lines used in this study were NOL3 (established at Nagoya University), OCI-LY3, OCI-LY4, OCI-LY7, OCI-LY13.2 and OCI-LY17 (DLBCL, kindly provided by Dr R Dalla-Favera of Columbia University, New York, NY, USA) (Tweeddale et al., 1987) . All 57 cases including 51 patients and six cell lines were analysed by RT-PCR. We conducted our array CGH based on the result of RT-PCR analysis. A total of 18 samples with aberrant transcripts, one sample without any transcript, eight samples with only wild-type transcripts were selected for our contig array CGH.
DNA and RNA isolation, RT
DNA of tumor specimens from DLBCL patients was prepared with the standard phenol-chloroform method, and total cellular RNA with the guanidine thiocyanate-cesium chloride method (Chirgwin et al., 1979) . Normal DNA for use with array CGH was obtained from peripheral-blood lymphocytes from a normal male. RT was performed using SuperScriptII (Life Technologies, Inc., Division of Life Technologies, Inc., Gaithersburg, MD, USA). Briefly, each 5 mg of total RNA was reverse-transcribed into cDNA dissolved in 40 ml of distilled water.
RT-PCR and direct sequence
Two rounds of PCR were designed to amplify the FHIT gene by using a nested strategy and primers. cDNA (0.5 ml) was amplified in a 50 ml reaction mixture containing 2.5 U of r-Taq DNA polymerase (Takara Bio Inc., Otsu, Japan), 2.5 mM dNTPs, 10 Â PCR buffer, 100 mM of primers F1 (5 0 -ATCCTG-GAAGCTTTGAGCTCA-3 0 ) and R1 (5 0 -TCACTGGTTGAA-GAATACAGGA-3 0 ), as reported by Ohta et al. (1996) . Firstround PCR amplification was performed for initial denatura- DNA sequences were compared with those in the GenBank databases by utilizing the Blast program available at web site, http://www.ncbi.nlm.nih.gov.
Preparation of BAC clones for array CGH
BAC clones used in the array CGH were selected from RP-11 libraries (http://bacpac.chori.org/) and obtained from the BACPAC Resources Center at the Children's Hospital Oakland Research Institute (Oakland, CA, USA, USA). Clones were isolated from their bacterial cultures with the relevant antibiotics and extracted with a plasmid Mini-Kit (QUIAGEN, Germantown, MD, USA). The exact location of each clone was determined by standard FISH analysis. DOP-PCR was performed on the DNA of BAC clones as described before . DOP-PCR products were dissolved in 30 ml of TE (100 mM Tris-HCl and 1 mM EDTA, pH 7.5) buffer, and 10 ml of the Solution I (Takara Bio Inc.) was added to each of the products, which were then spotted in triplicate onto the Hubble-activated slides (Takara Bio Inc.) using the Stampman Arrayer (Nippon Laser & Electronics Lab., Nagoya, Japan) with a split pin. Slides were fixed in 0.2% SDS for 2 min and in 0.3 N NaOH for 5 min, then dehydrated with 100% cold ethanol for 3 min, and finally air-dried.
Array hybridization
DNA preparation, labeling, array fabrication and hybridization were performed according to the method described by Pinkel et al. (1998) with minor modifications . Scanning analysis was carried out with the Agilent Micro Array Scanner (Agilent Technologies, Palo Alto, CA, USA). Array images thus acquired were analysed with the Genepix Pro 4.1 (Axon Instruments, Inc., Foster City, CA, USA). The total intensities and fluorescence intensity ratio of the two dyes for each spot were calculated.
Data analysis
The Cy3/Cy5 intensity ratios of every spot were converted into log2 ratios. The log2 ratio of each clone was normalized to the median log2 ratio of the five control clones, after which the average of triplicate spots was calculated. Spots with weak (50% or less of intensity of the average intensity of the whole spot) Cy3 or Cy5 intensity were excluded from analysis. Furthermore, clones with a scatter log2 ratio showing a difference of more than 0.2 between the maximum and minimum log2 ratio of triplicate spots were also excluded. In total, approximately 1% of the clones were excluded. A BAC clone with a log2 ratio of À0.2 or less was defined as loss region.
